Primary hepatic adenoid cystic carcinoma: A case report and review of literature

Table 1 Postoperative laboratory findings at 7-month follow-up

Parameter	Result	Reference range
Liver function tests
ALT	11 U/L	7-40 U/L
AST	22 U/L	13-35 U/L
ALP	109 U/L	50-135 U/L
GGT	19 U/L	7-45 U/L
Total bilirubin	10.8 μmol/L	0.0-21.0 μmol/L
Tumor markers
AFP	2.84 ng/mL	0.00-8.78 ng/mL
CA19-9	6.09 IU/mL	< 37.00 IU/mL
CA125	5.71 U/mL	< 35.00 U/mL
CA15-3	19.20 U/mL	< 25.00 U/mL
CEA	1.22 ng/mL	0.00-5.00 ng/mL

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; AFP: Alpha-fetoprotein; CA19-9: Cancer antigen 19-9; CA125: Cancer antigen 125; CA15-3: Cancer antigen 15-3; CEA: Carcinoembryonic antigen.

Table 2 Summary of reported cases of primary adenoid cystic carcinoma of the liver

	Ziarkiewicz-Wróblewska et al[8]1	Zhang et al[9]	Present case
Age/sex	21/female	44/male	59/female
Presentation	Incidental (pregnancy)	Epigastric pain, distension	Lower back pain
Tumor size (cm)	30	21	6
Tumor location	Nearly entire liver	Right lobe	Posterior segment, right lobe
Extent of disease	Confined to liver	Invasion of diaphragm and omentum	Confined to liver
Tumor markers	Within normal range	Elevated GGT, CA19-9	Within normal range
Treatment	Surgery	Surgery	Surgery + capecitabine
Follow-up (month)	NA	33	7
Outcome	NA	Death	No recurrence to date

¹Information for this case is derived from the English abstract, as the full-text article was not accessible.

Long-term follow-up information was not available in the English abstract. NA: Not available; GGT: Gamma-glutamyl transpeptidase; CA19-9: Carbohydrate antigen 19-9.